DCM
AVDL

Driehaus Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Driehaus Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-470,341
Closed -$6.61M – 384
2024
Q2 		$6.61M Sell
470,341
-5,096
-1% -$83.1K 0.06% 248
2024
Q1 		$8.03M Buy
+475,437
New +$7.08M 0.08% 253
2020
Q2 		– Sell
-490,878
Closed -$3.9M – 383
2020
Q1 		$3.9M Buy
+490,878
New +$3.77M 0.13% 172
2015
Q2 		– Sell
-118,042
Closed -$2.12M – 518
2015
Q1 		$2.12M Sell
118,042
-95,363
-45% -$1.49M 0.07% 323
2014
Q4 		$3.66M Buy
+213,405
New +$3.05M 0.15% 191

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Driehaus Capital Management's AVDL Position: Q3 2024 in Review

Driehaus Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 470,341 shares — an estimated $6.61M sold.

Driehaus Capital Management first reported a position in AVDL in Q4 2014 and held it in 5 quarters. The position peaked at $8.03M in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Driehaus Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 470,341 Avadel Pharmaceuticals shares in Q3 2024, an estimated $6.61M.
  • Driehaus Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Driehaus Capital Management's Avadel Pharmaceuticals position peaked at $8.03M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Driehaus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.